

Bangladesh Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

ision Letter: 10 M cember 2014) Partnership Fram title: NVS, IPV rc e: Inactivated Poli	nework Agreement	s the previous Decisic	on Letter for IPV						
ision Letter: 10 M cember 2014) Partnership Fram title: NVS, IPV rc e: Inactivated Poli	March 2016 (replace nework Agreement	s the previous Decisic	on Letter for IPV						
cember 2014) Partnership Fram title: NVS, IPV ro e: Inactivated Poli	nework Agreement		on Letter for IPV						
title: NVS, IPV ro	outine	: 24 June 2013							
e: Inactivated Poli									
	io Vaccine (IPV)								
			6. Vaccine type: Inactivated Polio Vaccine (IPV)						
 Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID 									
8. Programme duration ² : 2014 - 2018									
 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes. 									
2014-2015	2016	2017	Total ³						
US\$9,673,130	US\$6,935,000	US\$5,559,000	US\$22,167,130						
ι	JS\$9,673,130		US\$9,673,130 US\$6,935,000 US\$5,559,000 Dduction grant: Not applicable						

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2017. The total amount has been revised from the previous endorsement levels based on changes to target populations, indicative wastage rates and introduction dates (where applicable). These reductions have been applied from 2016.



11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

Type of supplies to be purchased with GAVI funds in each year (1418-BGD-25b-X)	2016
Number of IPV vaccines doses	3,489,100
Annual Amounts (US\$)	US\$6,769,000

Type of supplies to be purchased with GAVI funds in each year (1418-BGD-25b-Y)	2016	\$
AD Syringes	3,250,200)
Re-constitution Syringes		1
Safety Boxes	35,775	5
Annual Amounts (US\$)	US\$166,000	ז ו
12. Procurement agency: UNICEF		
13. Self-procurement: Not applicable		
14. Co-financing obligations: Not applicable		
Gavi's usual co-financing requirements do not apply to IPV		
 is encouraged to contribute to vaccine and/or supply costs	for IPV.	
15. Operational support for campaigns: Not applicable.		
16. Additional reporting requirements:		
Reports and other information	Due dates	
To prepare for the annual procurement of vaccines, Country s submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffe stock, wastage rates, any proposed changes in presentation of	r	

 In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.
 To be agreed with Secretariat

 17. Financial clarifications: Country shall provide the following clarifications to Gavi*: Not applicable

 *Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements

minimum co-financing levels and vaccines received.

18. Other conditions: Not applicable

Signed by, On behalf of Gavi

dellar . Ho bi

Hind Khatib-Othman Managing Director, Country Programmes 10 March 2016

⁴ This is the amount that Gavi has approved.